




**Supplementary Figure 1. Mechanical characterization of lung hydrogels using micro-indentation method.** a) Representative image of lung hydrogel after 24 hours of swelling in 1X PBS. Modulus of the hydrogel was measured using micro-indentation method with a 1 mm diameter flat probe. b) Effective modulus of 10 wt% 4-arm PEG-maleimide hydrogel without bioactive peptide ligands using micro-indentation replicated the lung modulus measured using the same method. c) Effective modulus of 10 wt% 4-arm PEG-maleimide hydrogel containing different molar concentrations of MMP-degradable peptide crosslinkers using micro-indentation method. The tested peptide crosslinker molar concentrations were 0%, 13% and 25%. d) Effective modulus of 10 wt% 4-arm PEG-maleimide hydrogel containing different molar concentrations of integrin-binding peptide moieties using micro-indentation method. The tested peptide molar concentrations were 0 mM, 1 mM, 2 mM, 4 mM, and 6 mM.




**Supplementary Figure 2. Functional validation of lung integrin-binding peptides.** a) Schematics of the cell attachment assay where cells were seeded on glass coverslips functionalized with lung integrin-binding peptides and the cells were imaged for 2 hours. b) Representative images of HLFs at time t = 0 and t = 2 hours. c) Representative images of MDA-MB-231 LM2 cells at time t = 0 and t = 2 hours. d) Cell area fold change for MDA-MB-231 cells in compared to negative control. e) Representative images of MDA-MB-231 cells at time t = 0 and t = 2 hours. f) Cell area fold change for BT474 cells in compared to negative control. g) Representative images of BT474 cells at time t = 0 and t = 2 hours.




**Supplementary Figure 3. Competitive cell attachment assay on lung integrin-binding peptides using HLFs.** a) Schematics of the competitive cell binding assay where HLFs pre-incubated with individual lung integrin-binding peptides were seeded on glass coverslips functionalized with lung integrin-binding peptide cocktail and the cells were imaged for 2 hours. b) Representative images of HLFs (pre-incubated with individual binding peptides) at time  $t = 0$  and  $t = 2$  hours.



**Supplementary Figure 4. Integrin-specific cell attachment with lung integrin-binding peptides.** a) Schematics of the competitive cell binding assay where HLFs pre-incubated with cilengitide were seeded on glass coverslips functionalized with lung integrin-binding peptide cocktail and the cells were imaged for 2 hours. b) Cell area fold change 2 hours after seeding HLFs (pre-incubated with cilengitide) onto glass coverslips functionalized with integrin-binding peptide cocktail relative to a negative control (cells not pre-incubated with cilengitide).



**Supplementary Figure 5. Fibroblast phenotype and activation on TCPS.** (a) Representative fluorescent images of HLFs cultured on TCPS with or without pro-fibrotic cytokine, TGF- $\beta$ 1 showing  $\alpha$ -SMA (orange), and FAP (green) expressions along with merged HLF images with nuclei staining with DAPI (blue). (b) Fold change in cell count for non-activated (cultured without TGF- $\beta$ 1) and activated (cultured with TGF- $\beta$ 1) HLFs on TCPS representing cell proliferation characteristics. (c) Quantification of  $\alpha$ -SMA expression from non-activated and activated HLFs cultured on TCPS. (d) Quantification of FAP expression from non-activated and activated HLFs cultured on TCPS. (e) Percentage of proliferative ki67+ cells in non-activated and activated HLF cultures on TCPS. (f) Cell area for non-activated and activated HLFs cultured on TCPS. (g) Cell circularity for non-activated and activated HLFs cultured on TCPS.



**Supplementary Figure 6. List and quantities of metastatic lung-specific integrin-binding and MMP-degradable peptides.** a) Schematic of identification of metastatic lung ECM-specific integrin-binding and MMP-degradable peptides. b) List of identified integrin-binding peptide domains with their relative quantities corresponding to metastatic lung ECM proteins. c) List of identified MMP-degradable peptide domains with their relative quantities corresponding to the different MMPs.